An updated version of Moderna’s Covid vaccine produces an eightfold increase in antibody levels against the Omicron variant, according to early trial results, raising hopes for a once-a-year booster to protect against the disease.
The vaccine is the first “bivalent” formulation to combine protection against Omicron and the original strain of coronavirus, and is the company’s leading candidate for upcoming autumn booster programmes.
